November 12, 2015
Roche exits four manufacturing sites, job cuts imminent
Swiss-based Roche plans to exit four manufacturing sites globally. Workforce reduction is imminent.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
November 12, 2015
Silence Therapeutics welcomes new board member
Silence Therapeutics plc, a London-headquartered drug development company, dealing with the delivery of novel RNA interference (RNAi) therapeutics for the treatment…
November 12, 2015
Study shows IONA test can predict the presence of Down’s, Edward’s, and Patau’s syndrome
Study demonstrates the IONA test can accurately predict the presence of the trisomies 21, 18, and 13. Being user-friendly, cost effective and CE-marked will overcome some of the limitations of existing commercial technologies to facilitate implementation in local laboratories.
November 11, 2015
4D pharma gets OK for clinical trial of Thetanix
4D pharma has obtained regulatory and ethical approval for a phase 1 clinical trial in respect of Thetanix.
November 11, 2015
Biofrontera’s business not affected by ongoing approval processes
Biofrontera has announced that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.
November 6, 2015
AstraZeneca buys ZS Pharma
AstraZeneca has entered into a definitive agreement to acquire Nasdaq-listed ZS Pharma, a biopharmaceutical company based in San Mateo, California.
November 6, 2015
Sanofi and Lexicon to develop sotagliflozin (for diabetics)
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
November 5, 2015
Quantum Pharma’s Colonis launches medical devices for side effects of cancer treatment
Colonis, part of Quantum Pharma’s newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat…
November 5, 2015
Sanofi and Hanmi in $3.5B license agreement (developing diabetes treatments)
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
November 5, 2015
Redx makes managerial changes
Redx, the drug discovery and development company, has made two senior management appointments.
The company on Thursday said that Nicholas Adams is new as Chief Business Officer and Dr Matilda Bingham has been promoted to Executive Director of Redx Oncology Ltd, the Group’s oncology subsidiary.